BIOSECURE Act Amendment Left Out Of NDAA Consideration

By Jessica Karins / June 12, 2024 at 3:37 PM

Legislation that would ban American companies and federal agencies from contracting with some foreign-owned biotechnology firms failed to make the House Rules Committee’s list of floor amendments to the fiscal 2025 National Defense Authorization Act (NDAA), cutting off a route for passage of a bill that has already had an impact of the biologics industry.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.